- QIAcuity Digital PCR now provides the ability to simultaneously detect up to 12 targets from a single biological sample, more than doubling the previous capability of up to five targets
- No hardware changes are required to improve capability thanks to the new QIAcuity programming (ETR:) 3.1 Update and launch QIAcuity High Multiplex Probe PCR Kit
- QIAcuity's new digital PCR capabilities help make laboratory work more productive and cost-effective by saving time, reagent consumption and the use of precious sample materials
VENELO, Netherlands–(BUSINESS WIRE)–QIAGEN (NYSE: QGEN; Frankfurt Standard: QIA) today announced a significant increase in the powerful capabilities of the QIAcuity Digital PCR (dPCR) System ) with a more than two-fold increase in the number of targets that can be analyzed simultaneously from a single biological sample.
The new capabilities overcome the assay design challenges faced by multiple PCR methods currently available, making QIAcuity digital PCR ideal for applications such as translational research, microbiome analysis, pathogen detection, and development of cell and gene therapies.
With the software upgrade and launch of the new QIAcuity High Multiplex Probe PCR Kit, customers can now analyze up to 12 targets simultaneously compared to the previous version which offered up to five targets, using their existing instruments without any hardware changes.
This upgrade provides QIAcuity customers with powerful technology that amplifies and detects multiple targets within a single interaction. By combining multiple PCR assays, researchers can now maximize sample utilization while reducing time and reagent consumption while accelerating the process to gain deep biological insights.
Analyzing more targets simultaneously from a single biological sample is an important step in making QIAcuity an even better choice for leading-edge dPCR applications,” said Nitin Sood, Senior Vice President and Head of Life Sciences Business Area at QIAGEN. We are exploring ways to leverage QIAcuity's capabilities to help researchers gain a deeper biological understanding of any sample type in a cost-effective way without tedious optimization or fear of inaccurate quantification.
Adoption of the QIAcuity digital PCR tool is strong, with more than 2,700 cumulative placements at the end of 2024 and citations in more than 550 publications. Major clients include pharmaceutical and biotechnology companies, academic and research organizations, and forensic laboratories. In fall 2024, QIAGEN expands its dPCR portfolio to include clinical assays with the launch of QIAcuityDx, designed to address customer segments and clinical applications and to enhance the QIAcuity family.
The QIAcuity High Multiplex Probe PCR Kit contains a ready-to-use master mix optimized for microfluidics in QIAcuity Nanoplates and allows users to easily perform high-order multiplexing on existing QIAcuity instruments. The kit improves the specificity and efficiency of probe-based digital PCR to provide accurate one-way analysis, or up to 12 duplex analyses.
As a prerequisite for using the QIAcuity High Multiplex Probe PCR Kit, QIAcuity Software 3.1 offers essential features for high-order multiplexing such as interference compensation that corrects signal interference between targets. This enables researchers to confidently analyze more targets in parallel from a single, unsplit sample.
The QIAcuity dPCR catalog and custom assays for copy number variation (CNV) analysis and microbial detection have been redesigned to support up to 12 pairwise reactions. These assays are available through QIAGEN's GeneGlobe platform.
The combination of cutting-edge software and innovative chemistry makes QIAcuity dPCR a premium solution for high-order multiplexing. It enhances workflow by providing greater target capacity and improved data reliability while QIAcuity remains the highest throughput dPCR system and is highly automation friendly.
QIAGEN's QIAcuity digital PCR platform uses nanoplates to break up a sample into thousands of small sections and then reads the reaction in each section simultaneously to identify even the weakest signals from DNA and RNA. The platform integrates sectioning, thermal cycling and imaging into a streamlined multiplex workflow, reducing processing times from six hours to just two hours. Available in single-, four- and eight-panel versions, the platform meets the needs of a wide range of laboratory sizes and throughput requirements.
For more information about QIAcuity's new multiplexing capabilities, please visit: https://www.qiagen.com/applications/digital-pcr/beginners/dpcr-multiplexing
About QIAGEN
QIAGEN NV, a Netherlands-based holding company, is a leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the essential elements of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissues and other materials. These screening techniques make biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant and actionable insights. Automation solutions tie these elements together into seamless, cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers worldwide in molecular diagnostics (human healthcare) and life sciences (academia, pharmaceutical R&D, industrial applications, primarily forensics). As of September 30, 2024, QIAGEN employed more than 5,800 people in more than 35 locations around the world. More information can be found at https://www.qiagen.com.
Forward-looking statement
Certain statements in this press release may be deemed forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent any statements contained herein relate to QIAGEN's products, timing of launch and development, commercialization and/or regulatory approvals, financial and operational projections, growth and expansion, collaborations, markets, strategy or operating results, including without limitation , Expected adjusted net sales and adjusted diluted earnings results are forward-looking, and these statements are based on current expectations and assumptions that involve a number of uncertainties and risks. These uncertainties and risks include, but are not limited to, risks associated with managing growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), volatility of operating results, allocations between classes of customers, and commercial development. Our product markets to customers in academia, pharmaceutical, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; a race; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN products (including fluctuations resulting from general economic conditions, the level and timing of customer financing, budgets and other factors); our ability to obtain regulatory approval for our products; difficulties in successfully adapting QIAGEN products to integrated solutions and producing these products; QIAGEN's ability to identify and develop new products and to differentiate and protect our products from those of competitors; market acceptance of new QIAGEN products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, weather or transportation delays, natural disasters, political or public health crises, their impact on demand for our products and other aspects of our business, or other force majeure events; as well as the possibility that anticipated benefits related to recent or pending acquisitions may not be realized as expected; and other factors discussed under the heading Risk Factors in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions contained in the reports QIAGEN has filed with or filed with the U.S. Securities and Exchange Commission.
Source: QIAGEN NV
Category: Companies
View source version on Businesswire.com: https://www.businesswire.com/news/home/20250109845369/en/
Qiagen:
Investor relations
John Gilardi +49 2103 29 11711
Dominica Martorana +49 2103 29 11244
Email: ir@QIAGEN.com
Public relations
Thomas Thöringer +49 2103 29 11826
Lisa Specht +49 2103 29 14181
Email: pr@QIAGEN.com
Source: QIAGEN NV
